US4158581094 - Common Stock
HARROW INC
NASDAQ:HROW (5/10/2024, 7:00:01 PM)
After market: 11.6 0 (0%)11.6
+1.31 (+12.73%)
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 217 full-time employees. The company went IPO on 2013-02-08. The firm is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. The company provides comprehensive portfolio of prescription and non-prescription pharmaceutical products. The firm offers pharmaceutical products for ophthalmic surgeries in the United States, as well as medications prescribed to treat patients managing chronic and acute eye conditions, such as dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. The company serves over 10,000 doctors, hospitals, and ambulatory service centers (ASCs) and regularly ship to over 1,500 institutional accounts each month.
HARROW INC
102 Woodmont Blvd, Suite 610
Nashville TENNESSEE 37205
P: 16157334731
CEO: Mark L. Baum
Employees: 217
Website: https://www.harrow.com/
Here you can normally see the latest stock twits on HROW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: